top of page
2020.jpg

Dominique Joubert and his team wish you all the best for the New Year and thank you for your interest in the perspectives that the targeting of hPG80 (circulating progastrin) brings in the fight against cancer.

 

2019, a year in which our hospital partners and us have initiated a discreet revolution that has yet to be named, ends with two facts that we are particularly pleased to share with you as a first:

 

 

Some details: This publication shows in particular that hPG80 is expressed by the tumour and is present in the blood of patients with different types of cancer. We provide data from two retrospective kinetic studies in which blood samples were routinely collected from cancer patients undergoing different treatments and which showed strong associations between longitudinal hPG80 concentrations and the efficacy of cancer treatments. We provide data showing the decrease in hPG80 after surgery in a cohort of patients with peritoneal involvement due to gastrointestinal cancers treated with perioperative chemotherapy regimens and cytoreductive surgery. We are also showing the correlation between hPG80 levels and standard imaging in a cohort of patients with hepatocellular carcinoma treated with local or systemic therapies, including patients with no detectable alpha-fetoprotein levels. Finally, we show that targeting hPG80 with our humanized antibody decreases the self-renewal capacity of cancer stem cells of various origins

EBioMedicine Published by THE LANCET: https://www.sciencedirect.com/science/article/pii/S2352396419307844 ]

 

  • The second information we wish to share with you concerns the start of commercialization of the DxPG80 test in December 2019 (we have completed the commercial testing phase), for the effective clinical use of hPG80 detection and assay by hospital clinicians in several countries, precursors of new approaches to therapeutic efficacy and relapse monitoring.

 

A few details: Dosing hPG80 before, during and after treatment (surgery, chemotherapy, radiotherapy or targeted therapy such as immunotherapy) provides physicians with new information. Unlike other tumour markers that tend to give information only on tumour size, hPG80 seems to indicate the "energy/activity" of the tumour. The level of hPG80 is not only related to the presence of the tumour, but to the energy/activity of the cancer cells, which is mainly reflected by the activity of the cancer stem cells. To date, only the hPG80 assay provides information on the activity of cancer stem cells. 63 studies on the 5 continents (already performed, in progress or to be launched) focus on the value of the detection or assay of hPG80 in blood for the diagnosis and monitoring of cancer patients.

 

We are on the threshold of a medical revolution that each of us is calling for in the control of cancer!

 

As any revolution requires us to move beyond the comfort of existing models, it is now more than ever incumbent on us to be the active precursors of this change, each at our own level.

 

Let's meet this challenge together and 2020 will be an unforgettable year.

 

Here are our wishes for the New Year.

See you soon,

All ECS Progastrin and group teams.

20190424 LogoECS Progastrin2019.png
bottom of page